NueHealth has entered a three-year partnership agreement with GeneNews — a Canadian diagnostic products company — to offer its patients early cancer detection tests.
The Nashville-based pharmaceutical company Cumberland Pharmaceuticals received FDA clearance for a randomized, placebo-controlled Phase II clinical study. The study will investigate Portaban, a treatment the company developed for liver cyrossis patients.
Nicole Bradberry was named the next CEO of Captify Health, a gastroenterology care company that supports physician practices, health plans and health systems with technology-enabled services.
More articles on GI company news:
NueHealth, GeneNews partner to offer patients early CRC detection: 3 notes
FDA clears liver cyrossis drug for Phase II study: 4 notes
Captify Health taps Nicole Bradberry as next CEO: 5 takeaways
